{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:20:28Z","timestamp":1788481228659,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastric cancer (GC) is among the most common malignant tumors in China and leads in incidence across all cancer types. For over three decades, the standard treatment has been traditional chemotherapy, which often involves monotherapy with 5-fluorouracil (5-FU) or its combination with other drugs. Unfortunately, nearly all cases of GC eventually develop resistance to 5-FU, typically displaying a median time to progression that ranges from 0 to 8 months. Therefore, elucidating the mechanisms of acquired resistance to 5-FU in GC continues to be a critical focus of ongoing research. Various gene and protein expression analyses were conducted utilizing techniques such as RT-qPCR, Western blot, IF, and IHC staining. Cell viability and proliferation were assessed using the CCK-8 assays and colony formation assays, respectively. Interactions among HDAC3, HNF4A, and TYMS were explored using ChIP, Co-IP, and dual-luciferase reporter assays. Chidamide increased the sensitivity of GC cells to 5-FU through the downregulation of TYMS and HDAC3. Additionally, the treatment with chidamide led to increased acetylation of HNF4A at lysine 458, due to the suppression of HDAC3, which in turn decreased phosphorylation of HNF4A at serine 313. Chidamide promoted the sensitivity of GC to 5-FU by suppressing the HDAC3\/HNF4A\/TYMS axis. This research may provide a foundation for using chidamide to counteract resistance to 5-FU in GC.<\/jats:p>","DOI":"10.1038\/s41419-025-08247-y","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T04:07:04Z","timestamp":1764562024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chidamide enhances the sensitivity of gastric cancer to 5-fluorouracil chemotherapy by suppressing the HDAC3\/HNF4A\/TYMS axis"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaofei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0486-344X","authenticated-orcid":false,"given":"Xiaonan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"8247_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06368-w","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Tang L, Gong S, Xiao T, Yang H, Gu W, et al. USP7 inhibits the progression of nasopharyngeal carcinoma via promoting SPLUNC1-mediated M1 macrophage polarization through TRIM24. Cell Death Dis. 2023;14:852.","journal-title":"Cell Death Dis"},{"key":"8247_CR2","first-page":"26","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14:26\u201338.","journal-title":"Prz Gastroenterol"},{"key":"8247_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","volume":"22","author":"A Digklia","year":"2016","unstructured":"Digklia A. Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22:2403\u201314.","journal-title":"World J Gastroenterol"},{"key":"8247_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7150\/ijbs.10248","volume":"11","author":"ZY Xu","year":"2015","unstructured":"Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF, et al. 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci. 2015;11:284\u201394.","journal-title":"Int J Biol Sci"},{"key":"8247_CR5","doi-asserted-by":"publisher","first-page":"103184","DOI":"10.1016\/j.bioorg.2019.103184","volume":"91","author":"M Huang","year":"2019","unstructured":"Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: promising agents for breast cancer treatment. Bioorganic Chem. 2019;91:103184.","journal-title":"Bioorganic Chem"},{"key":"8247_CR6","first-page":"193","volume":"63","author":"L Liu","year":"2016","unstructured":"Liu L, Qiu S, Liu Y, Liu Z, Zheng Y, Su X, et al. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. Neoplasma. 2016;63:193\u2013200.","journal-title":"Neoplasma"},{"key":"8247_CR7","doi-asserted-by":"crossref","unstructured":"Attenello F, Raza SM, Dimeco F, Olivi A Chapter 22 - Chemotherapy for brain tumors with polymer drug delivery. In: Aminoff MJ, Boller F, Swaab DF, editors. Handbook of clinical neurology. 104: Elsevier; 2012. p. 339\u201353.","DOI":"10.1016\/B978-0-444-52138-5.00022-0"},{"key":"8247_CR8","doi-asserted-by":"publisher","first-page":"17182","DOI":"10.1021\/acsomega.0c01224","volume":"5","author":"K Gaurav","year":"2020","unstructured":"Gaurav K, Adhikary T, Satpati P. dUMP\/F-dUMP binding to thymidylate synthase: human versus mycobacterium tuberculosis. ACS Omega. 2020;5:17182\u201392.","journal-title":"ACS Omega"},{"key":"8247_CR9","doi-asserted-by":"crossref","unstructured":"Azwar S, Seow HF, Abdullah M, Faisal Jabar M, Mohtarrudin N. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology. 2021;10.","DOI":"10.3390\/biology10090854"},{"key":"8247_CR10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3324\/haematol.2017.181172","volume":"103","author":"J He","year":"2018","unstructured":"He J, Chen Q, Gu H, Chen J, Zhang E, Guo X, et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica. 2018;103:1369\u201379.","journal-title":"Haematologica"},{"key":"8247_CR11","doi-asserted-by":"crossref","unstructured":"Badie A, Gaiddon C, Mellitzer G. Histone deacetylase functions in gastric cancer: therapeutic target? Cancers. 2022;14.","DOI":"10.3390\/cancers14215472"},{"key":"8247_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s10565-021-09673-2","volume":"39","author":"SM Wu","year":"2023","unstructured":"Wu SM, Jan YJ, Tsai SC, Pan HC, Shen CC, Yang CN, et al. Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer. Cell Biol Toxicol. 2023;39:1873\u201396.","journal-title":"Cell Biol Toxicol"},{"key":"8247_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s12276-020-00551-1","volume":"53","author":"DD Lv","year":"2021","unstructured":"Lv DD, Zhou LY, Tang H. Hepatocyte nuclear factor 4\u03b1 and cancer-related cell signaling pathways: a promising insight into cancer treatment. Exp Mol Med. 2021;53:8\u201318.","journal-title":"Exp Mol Med"},{"key":"8247_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/gutjnl-2014-307918","volume":"65","author":"HR Chang","year":"2016","unstructured":"Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, et al. HNF4\u03b1 is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. 2016;65:19\u201332.","journal-title":"Gut"},{"key":"8247_CR15","doi-asserted-by":"crossref","unstructured":"DeLaForest A, Di Furio F, Jing R, Ludwig-Kubinski A, Twaroski K, Urick A, et al. HNF4A Regulates the formation of hepatic progenitor cells from human iPSC-derived endoderm by facilitating efficient recruitment of RNA Pol II. Gene. 2018;10.","DOI":"10.3390\/genes10010021"},{"key":"8247_CR16","doi-asserted-by":"publisher","first-page":"1197063","DOI":"10.3389\/fendo.2023.1197063","volume":"14","author":"B Beinsteiner","year":"2023","unstructured":"Beinsteiner B, Billas IML, Moras D. Structural insights into the HNF4 biology. Front Endocrinol. 2023;14:1197063.","journal-title":"Front Endocrinol"},{"key":"8247_CR17","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.xpro.2021.100497","volume":"2","author":"P Jiang","year":"2021","unstructured":"Jiang P, Ren L, Zhi L, Hu X, Xiao RP. Protocol for cell preparation and gene delivery in HEK293T and C2C12 cells. STAR Protoc. 2021;2:100497.","journal-title":"STAR Protoc"},{"key":"8247_CR18","doi-asserted-by":"crossref","unstructured":"Aleksandr I, Anil KG, Tero A. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acid Res. 2022;50:W739\u2013W743.","DOI":"10.1093\/nar\/gkac382"},{"key":"8247_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bcp.2016.03.010","volume":"108","author":"NG Leus","year":"2016","unstructured":"Leus NG, van der Wouden PE, van den Bosch T, Hooghiemstra WTR, Ourailidou ME, Kistemaker LE, et al. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-\u03baB p65 transcriptional activity. Biochem Pharm. 2016;108:58\u201374.","journal-title":"Biochem Pharm"},{"key":"8247_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-024-01283-9","volume":"31","author":"J Jia","year":"2024","unstructured":"Jia J, Ji W, Saliba AN, Csizmar CM, Ye K, Hu L, et al. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death. Cell Death Differ. 2024;31:405\u201316.","journal-title":"Cell Death Differ"},{"key":"8247_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5812\/ijem.3505","volume":"10","author":"A Ghasemi","year":"2012","unstructured":"Ghasemi A, Zahediasl S. Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab. 2012;10:486\u20139.","journal-title":"Int J Endocrinol Metab"},{"key":"8247_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.apsb.2016.07.003","volume":"6","author":"H Lu","year":"2016","unstructured":"Lu H. Crosstalk of HNF4\u03b1 with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B. 2016;6:393\u2013408.","journal-title":"Acta Pharm Sin B"},{"key":"8247_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4103\/0366-6999.176069","volume":"129","author":"JC Tang","year":"2016","unstructured":"Tang JC, Feng YL, Liang X, Cai XJ. Autophagy in 5-fluorouracil therapy in gastrointestinal cancer: trends and challenges. Chin Med J. 2016;129:456\u201363.","journal-title":"Chin Med J"},{"key":"8247_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551\u201369.","journal-title":"Molecules"},{"key":"8247_CR25","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/ijbs.45886","volume":"16","author":"N Ding","year":"2020","unstructured":"Ding N, You A, Tian W, Gu L, Deng D. Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation. Int J Biol Sci. 2020;16:2595\u2013611.","journal-title":"Int J Biol Sci"},{"key":"8247_CR26","doi-asserted-by":"publisher","first-page":"e6762","DOI":"10.1002\/cam4.6762","volume":"13","author":"D Li","year":"2024","unstructured":"Li D, Jin Y, Lin M, Zeng C, Guo Q, Liu Y, et al. Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world multicenter study. Cancer Med. 2024;13:e6762.","journal-title":"Cancer Med"},{"key":"8247_CR27","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s13577-023-00919-1","volume":"36","author":"L Yin","year":"2023","unstructured":"Yin L, Zhang Q, Xie S, Cheng Z, Li R, Zhu H, et al. HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway. Hum Cell. 2023;36:1564\u201377.","journal-title":"Hum Cell"},{"key":"8247_CR28","doi-asserted-by":"publisher","first-page":"819714","DOI":"10.3389\/fonc.2022.819714","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Yuan X, Wang Z, Li J, Liu Z, Wang Y, et al. Chidamide reverses fluzoparib resistance in triple-negative breast cancer cells. Front Oncol. 2022;12:819714.","journal-title":"Front Oncol"},{"key":"8247_CR29","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41419-021-04187-5","volume":"12","author":"K Xue","year":"2021","unstructured":"Xue K, Wu J-C, Li X-Y, Li R, Zhang Q-l, Chang J-J, et al. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed\/refractory B-cell lymphoma. Cell Death Dis. 2021;12:900.","journal-title":"Cell Death Dis"},{"key":"8247_CR30","doi-asserted-by":"publisher","first-page":"eadd3243","DOI":"10.1126\/sciadv.add3243","volume":"9","author":"LJ Eichner","year":"2023","unstructured":"Eichner LJ, Curtis SD, Brun SN, McGuire CK, Gushterova I, Baumgart JT, et al. HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer. Sci Adv. 2023;9:eadd3243.","journal-title":"Sci Adv"},{"key":"8247_CR31","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/leu.2017.130","volume":"31","author":"J Long","year":"2017","unstructured":"Long J, Fang WY, Chang L, Gao WH, Shen Y, Jia MY, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017;31:2761\u201370.","journal-title":"Leukemia"},{"key":"8247_CR32","doi-asserted-by":"crossref","unstructured":"Dubois V, Staels B, Lefebvre P, Verzi MP, Eeckhoute J. Control of cell identity by the nuclear receptor HNF4 in organ pathophysiology. Cells. 2020;9:2185.","DOI":"10.3390\/cells9102185"},{"key":"8247_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41419-023-05868-z","volume":"14","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Liu T, Qian W, Ji J, Cai Q, Jin Y, et al. HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer. Cell Death Dis. 2023;14:356.","journal-title":"Cell Death Dis"},{"key":"8247_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13000-017-0635-2","volume":"12","author":"P Juc\u00e1","year":"2017","unstructured":"Juc\u00e1 P, Corr\u00eaa S, Vignal GM, Accioly MTS, Lustosa SAS, Abdelhay E, et al. HNF4A expression as a potential diagnostic tool to discriminate primary gastric cancer from breast cancer metastasis in a Brazilian cohort. Diagn Pathol. 2017;12:43.","journal-title":"Diagn Pathol"},{"key":"8247_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00772-5","volume":"8","author":"SM Armour","year":"2017","unstructured":"Armour SM, Remsberg JR, Damle M, Sidoli S, Ho WY, Li Z, et al. An HDAC3-PROX1 corepressor module acts on HNF4\u03b1 to control hepatic triglycerides. Nat Commun. 2017;8:549.","journal-title":"Nat Commun"},{"key":"8247_CR36","doi-asserted-by":"crossref","unstructured":"Beinsteiner B, Billas IML, Moras D Structural insights into the HNF4 biology. Frontiers in Endocrinology. 2023;14.","DOI":"10.3389\/fendo.2023.1197063"},{"key":"8247_CR37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1210\/me.2006-0300","volume":"21","author":"K Sun","year":"2007","unstructured":"Sun K, Montana V, Chellappa K, Brelivet Y, Moras D, Maeda Y, et al. Phosphorylation of a conserved serine in the deoxyribonucleic acid binding domain of nuclear receptors alters intracellular localization. Mol Endocrinol. 2007;21:1297\u2013311.","journal-title":"Mol Endocrinol"},{"key":"8247_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/hep4.1505","volume":"4","author":"RM Florentino","year":"2020","unstructured":"Florentino RM, Fraunhoffer NA, Morita K, Takeishi K, Ostrowska A, Achreja A, et al. Cellular Location of HNF4\u03b1 is Linked With Terminal Liver Failure in Humans. Hepatol Commun. 2020;4:859\u201375.","journal-title":"Hepatol Commun"},{"key":"8247_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.bbrc.2011.06.033","volume":"410","author":"A Yokoyama","year":"2011","unstructured":"Yokoyama A, Katsura S, Ito R, Hashiba W, Sekine H, Fujiki R, et al. Multiple post-translational modifications in hepatocyte nuclear factor 4\u03b1. Biochem Biophys Res Commun. 2011;410:749\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"8247_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/alzrt259","volume":"6","author":"C Cook","year":"2014","unstructured":"Cook C, Stankowski JN, Carlomagno Y, Stetler C, Petrucelli L. Acetylation: a new key to unlock tau\u2019s role in neurodegeneration. Alzheimers Res Ther. 2014;6:29.","journal-title":"Alzheimers Res Ther"},{"key":"8247_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/brain\/aws013","volume":"135","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, et al. Acetylated tau, a novel pathological signature in Alzheimer\u2019s disease and other tauopathies. Brain. 2012;135:807\u201318.","journal-title":"Brain"},{"key":"8247_CR42","doi-asserted-by":"crossref","unstructured":"Ju J, Chen A, Deng Y, Liu M, Wang Y, Wang Y, et al. NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. Nature Communications. 2017;8.","DOI":"10.1038\/s41467-017-00988-5"},{"key":"8247_CR43","doi-asserted-by":"publisher","first-page":"e86200","DOI":"10.7554\/eLife.86200","volume":"12","author":"A Esc\u00f3s","year":"2023","unstructured":"Esc\u00f3s A, Diaz-Mora E, Pattison M, Fajardo P, Gonz\u00e1lez-Romero D, Risco A, et al. p38\u03b3 and p38\u03b4 modulate innate immune response by regulating MEF2D activation. eLife. 2023;12:e86200.","journal-title":"eLife"},{"key":"8247_CR44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.21147\/j.issn.1000-9604.2018.06.05","volume":"30","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Wang T, Geng C, Zhang Y, Zhang J, Ning Z, et al. Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. Chin J Cancer Res. 2018;30:605\u201312.","journal-title":"Chin J Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08247-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08247-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08247-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:54:39Z","timestamp":1767797679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08247-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8247"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08247-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental methods were performed in strict accordance with guidelines provided by the The First Affiliated Hospital of Zhengzhou University, [2024-KY-2002-003] and adhered to the American Physiological Society\u2019s \u201cGuides for the Care and Use of Laboratory Animals\u201d.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}